This Month in JNM

July 2, 2020

Editor’s Page—Unacceptable denials: Czernin and Allen-Auerbach provide a brief perspective on recent denials of coverage for validated radiolabeled theranostics. Page 939

Discussions with leaders—Thomas Beyer interviews Yasuhito Sasaki about his career as a leader in radiology, nuclear medicine, radiation oncology, and radiation studies, with a specific focus on radiation health effects. Page 940

Continuing Education—Imaging the immune environment: Iravani and Hicks offer an overview of the current status of 18F-FDG PET/CT in monitoring tumoral and systemic immune response, in the first of a 2-part series. Page 943

The State of the Art—Toward molecular nuclear cardiology: Werner and colleagues review today’s clinical cardiovascular molecular imaging and highlight the evolution of cardiovascular therapy beyond mechanical interventions and broadly targeted medications toward individualized molecule-targeted and molecular imaging–guided therapies. Page 951

Hot Topics—ISCHEMIA trial: Murthy and colleagues from the SNMMI Cardiovascular Council highlight results from this trial comparing the effects on major adverse cardiac outcomes of optimal medical therapy versus optimal medical therapy plus coronary revascularization in moderate-to-severe ischemia. Page 962

Focus on Molecular Imaging—Imaging cardiac amyloidosis: Masri and colleagues summarize evolving imaging approaches in cardiac amyloidosis, their molecular structural bases, and gaps in imaging capabilities as a result of parallel developments in pharmacotherapeutic options for this condition. Page 965

PET/CT in LVAD infection: Sohns and colleagues explore the value of 18F-FDG PET/CT for assessing the extent and severity of left-ventricular assist device infection and resulting effects in guiding patient management. Page 971

Imaging astroglia after infarction: Bascuñana and colleagues evaluate insights into heart–brain inflammation networking facilitated by 11C-methionine PET imaging after experimental myocardial infarction. Page 977

Postlobectomy lung function prediction: Arnon-Sheleg and colleagues compare quantitative analyses of 2D planar lung perfusion scintigraphy with SPECT/CT and estimate the accuracies of a nonimaging segment counting method, perfusion scintigraphy, and SPECT/CT in predicting pulmonary function after lobectomy. Page 981

PET versus CT after immunotherapy for NSCLC: Rossi and colleagues compare evaluation of first response to nivolumab using CT-based criteria and 18F-FDG PET response criteria in advanced non–small cell lung cancer. Page 990

Interim PET in DLBCL: Györke and colleagues assess the predictive and prognostic value of interim 18F-FDG PET after 2 cycles of immunochemotherapy in diffuse large B-cell lymphoma by applying combined visual and semiquantitative evaluation. Page 999

Early DNA damage response signaling: Knight and colleagues investigate whether 111In-anti-γH2AX-TAT SPECT allows visualization of the DNA damage repair marker γH2AX in high-grade pancreatic intraepithelial neoplasias in an engineered mouse model of pancreatic ductal adenocarcinoma. Page 1006

Predicting PRRT outcomes: Pauwels and colleagues report on the utility of pretherapeutic and early interim 68Ga-DOTATOC PET tumor uptake, volumetric parameters, and an inflammation-based index for predicting outcomes in 90Y-DOTATOC peptide-receptor radionuclide therapy in neuroendocrine tumor patients. Page 1014

PET/MRI with DWI to assess GEP NETs: Adams and colleagues test functional 3D SUV apparent diffusion coefficient parameters and arterial tumor enhancement in accurately characterizing gastroenteropancreatic neuroendocrine tumors. Page 1021

Single-time-point dosimetry: Hänscheid and Lassmann offer perspective on the potential of SPECT/CT cameras to directly display absorbed doses and discuss a related article in this issue of JNM. Page 1028

Featured Clinical Investigation Article—Single-time-point 177Lu-PSMA dosimetry: Jackson and colleagues propose a novel approach to radiation dosimetry in targeted nuclear medicine therapies to enable dose computation from a single posttreatment SPECT scan. Page 1030

PSMA PET before and after SLND: Farolfi and colleagues analyze patterns of persistent versus recurrent or new prostate-specific membrane antigen ligand PET lesions in patients with prostate-specific antigen persistence after salvage lymph node dissection. Page 1037

Innate immunity maps in MS: Bodini and colleagues generate individual maps of white matter innate immune cell activation using 18F-DPA-714 translocator protein PET and correlate these with trajectories of worsening disability in patients with multiple sclerosis. Page 1043

Cerebral P-glycoprotein induction: Zoufal and colleagues investigate whether 11C-metoclopramide PET can measure P-glycoprotein induction at the blood–brain barrier in a β-amyloidosis mouse model and in wild-type mice and discuss implications for Alzheimer disease applications. Page 1050

Featured Article of the Month—212Pb-anti-CD38 in multiple myeloma: Quelven and colleagues explore the potential of α-radioimmunotherapy with 212Pb-daratumumab (anti-CD38) in in vitro and in vivo models of multiple myeloma. Page 1058

Optical imaging with exendin-IRDye 800CW: Boss and colleagues detail a novel method for targeted near-infrared fluorescence imaging of glucagonlike peptide 1 receptor–positive lesions using the GLP-1 agonist exendin-4 labeled with IRDye 800CW. Page 1066

Photoradiosynthesis of 89Zr-antibodies: Klingler and colleagues use a photoradiochemical approach to produce 89Zr-radiolabeled onartuzumab, a monovalent antihuman hepatocyte growth factor receptor antibody, starting directly from the fully formulated drug. Page 1072

Early detection of hepatic micrometastasis: Yu and colleagues assess the performance of photoacoustic imaging in detecting hepatic micrometastases from melanoma at a very early stage and in guiding tumor resection by intraoperative guidance. Page 1079